Comparative Pharmacology
Head-to-head clinical analysis: DOLENE versus DURAMORPH PF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLENE versus DURAMORPH PF.
DOLENE vs DURAMORPH PF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.
None Documented
None Documented
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Terminal elimination half-life of morphine is approximately 2-4 hours in adults. In neonates and elderly, half-life may be prolonged (up to 4.5-6.5 hours). Context: half-life may be extended in renal impairment due to accumulation of active metabolites.
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Primarily renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, with 10% as unchanged morphine). Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic